Methods of treating of diabetes and obesity using FGF21 mutants
The invention provides methods of treating diabetes, reducing triglyceride levels, and treating obesity by administering to a subject in need there a fusion protein comprising an FGF21 mutant.
1. A method for treating diabetes comprising administering to a human patient in need thereof a fusion protein comprising (a) an IgG constant domain; (b) a linker sequence fused to the IgG constant domain; and (c) an FGF21 mutant fused to the linker sequence and comprising the amino acid sequence of SEQ ID NO: 4, wherein an arginine residue has been substituted for the leucine residue at position 98 and a glycine residue has been substituted for the proline residue at position 171.
2. The method of claim 1 , wherein the linker sequence comprises GGGGGSGGGSGGGGS (SEQ ID NO:23).
3. The method of claim 1 , wherein the IgG constant domain comprises SEQ ID NO: 13.
4. The method of claim 1 , wherein the linker sequence comprises GGGGGSGGGSGGGGS (SEQ ID NO:23) and the IgG constant domain comprises the amino acid sequence of SEQ ID NO: 13.
5. The method of claim 4 , wherein the N terminus of the linker is fused to the C terminus of the IgG constant domain and the N terminus of the FGF21 mutant is fused to the C terminus of the linker.
6. The method of claim 1 , wherein the FGF21 mutant further comprises 1 to 10 amino acid residues fused to the C-terminus of the FGF21 mutant.
7. The method of claim 6 , wherein the 1 to 10 amino acid residues are selected from the group consisting of glycine, proline and combinations thereof.
8. The method of claim 1 , wherein the FGF21 mutant comprises: (a) an amino-terminal truncation of no more than 8 amino acid residues, wherein the polypeptide is capable of lowering blood glucose in a mammal; (b) a carboxyl-terminal truncation of no more than 12 amino acid residues, wherein the polypeptide is capable of lowering blood glucose in a mammal; or (c) an amino-terminal truncation of no more than 8 amino acid residues and a carboxyl-terminal truncation of no more than 12 amino acid residues.
9. A method for treating diabetes comprising administering to a human patient in need thereof a fusion protein comprising (a) an IgG constant domain; (b) a linker sequence fused to the IgG constant domain; and (c) an FGF21 mutant fused to the linker sequence and comprising the amino acid sequence of SEQ ID NO: 4, wherein (a) an arginine residue has been substituted for the leucine residue at position 98, (b) a glycine residue has been substituted for the proline residue at position 171, and (c) (i) the tyrosine at position 179 has been substituted with a phenylalanine, proline, alanine, serine or glycine; (ii) the alanine at position 180 has been substituted with a glutamic acid, glycine, proline, or serine; or (iii) the serine at position 181 has been substituted with a lysine, glycine, threonine, alanine, leucine, or proline.
10. A method of reducing triglyceride levels in a patient, improving glucose tolerance in a patient, lowering body weight in a patient, or lowering insulin levels in a patient, the method comprising administering to a human patient in need thereof a fusion protein comprising (a) an IgG constant domain; (b) a linker sequence fused to the IgG constant domain; and (c) an FGF21 mutant fused to the linker sequence and comprising the amino acid sequence of SEQ ID NO: 4, wherein an arginine residue has been substituted for the leucine residue at position 98 and a glycine residue has been substituted for the proline residue at position 171.
11. The method of claim 10 , wherein the linker sequence comprises GGGGGSGGGSGGGGS (SEQ ID NO:23).
12. The method of claim 10 , wherein the IgG constant domain comprises SEQ ID NO: 13.
13. The method of claim 10 , wherein the linker sequence comprises GGGGGSGGGSGGGGS (SEQ ID NO:23) and the IgG constant domain comprises the amino acid sequence of SEQ ID NO: 13.
14. The method of claim 13 , wherein the N terminus of the linker is fused to the C terminus of the IgG constant domain and the N terminus of the FGF21 mutant is fused to the C terminus of the linker.
15. The method of claim 10 , wherein the FGF21 mutant further comprises 1 to 10 amino acid residues fused to the C-terminus of the FGF21 mutant.
16. The method of claim 15 , wherein the 1 to 10 amino acid residues are selected from the group consisting of glycine, proline and combinations thereof.
17. The method of claim 10 , wherein the FGF21 mutant comprises: (a) an amino-terminal truncation of no more than 8 amino acid residues, wherein the polypeptide is capable of lowering blood glucose in a mammal; (b) a carboxyl-terminal truncation of no more than 12 amino acid residues, wherein the polypeptide is capable of lowering blood glucose in a mammal; or (c) an amino-terminal truncation of no more than 8 amino acid residues and a carboxyl-terminal truncation of no more than 12 amino acid residues.
18. The method claim 10 , wherein the patient has diabetes.
19. A method of reducing triglyceride levels in a patient, improving glucose tolerance in a patient, lowering body weight in a patient, or lowering insulin levels in a patient, the method comprising administering to a human patient in need thereof a fusion protein comprising (a) an IgG constant domain; (b) a linker sequence fused to the IgG constant domain; and (c) an FGF21 mutant fused to the linker sequence and comprising the amino acid sequence of SEQ ID NO: 4, wherein (a) an arginine residue has been substituted for the leucine residue at position 98, (b) a glycine residue has been substituted for the proline residue at position 171, and (c) (i) the tyrosine at position 179 has been substituted with a phenylalanine, proline, alanine, serine or glycine; (ii) the alanine at position 180 has been substituted with a glutamic acid, glycine, proline, or serine; or (iii) the serine at position 181 has been substituted with a lysine, glycine, threonine, alanine, leucine, or proline.
20. A method for treating obesity comprising administering to a human patient in need thereof a fusion protein comprising (a) an IgG constant domain; (b) a linker sequence fused to the IgG constant domain; and (c) an FGF21 mutant fused to the linker sequence and comprising the amino acid sequence of SEQ ID NO: 4, wherein an arginine residue has been substituted for the leucine residue at position 98 and a glycine residue has been substituted for the proline residue at position 171, wherein administration of the fusion protein reduces body weight in the human patient.
21. The method of claim 20 , wherein the linker sequence comprises GGGGGSGGGSGGGGS (SEQ ID NO:23).
22. The method of claim 20 , wherein the IgG constant domain comprises SEQ ID NO: 13.
23. The method of claim 20 , wherein the linker sequence comprises GGGGGSGGGSGGGGS (SEQ ID NO:23) and the IgG constant domain comprises the amino acid sequence of SEQ ID NO: 13.
24. The method of claim 23 , wherein the N terminus of the linker is fused to the C terminus of the IgG constant domain and the N terminus of the FGF21 mutant is fused to the C terminus of the linker.
25. The method of claim 20 , wherein the FGF21 mutant further comprises 1 to 10 amino acid residues fused to the C-terminus of the FGF21 mutant.
26. The method of claim 25 , wherein the 1 to 10 amino acid residues are selected from the group consisting of glycine, proline and combinations thereof.
27. The method of claim 20 , wherein the FGF21 mutant comprises: (a) an amino-terminal truncation of no more than 8 amino acid residues, wherein the polypeptide is capable of lowering blood glucose in a mammal; (b) a carboxyl-terminal truncation of no more than 12 amino acid residues, wherein the polypeptide is capable of lowering blood glucose in a mammal; or (c) an amino-terminal truncation of no more than 8 amino acid residues and a carboxyl-terminal truncation of no more than 12 amino acid residues.
28. A method for treating obesity comprising administering to a human patient in need thereof a fusion protein comprising (a) an IgG constant domain; (b) a linker sequence fused to the IgG constant domain; and (c) an FGF21 mutant fused to the linker sequence and comprising the amino acid sequence of SEQ ID NO: 4, wherein (a) an arginine residue has been substituted for the leucine residue at position 98, (b) a glycine residue has been substituted for the proline residue at position 171, and (c) (i) the tyrosine at position 179 has been substituted with a phenylalanine, proline, alanine, serine or glycine; (ii) the alanine at position 180 has been substituted with a glutamic acid, glycine, proline, or serine; or (iii) the serine at position 181 has been substituted with a lysine, glycine, threonine, alanine, leucine, or proline, wherein administration of the fusion protein reduces body weight in the human patient.